top
Please input keywords
Order
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1 plus/hPD-L1 mice
Strain Name C57BL/6N-Pdcd1tm3(PDCD1)BcgenCd274tm1(CD274)Bcgen/Bcgen Common Name  B-hPD-1 plus/hPD-L1 mice
Background C57BL/6 Catalog number 112550
Related Genes 

CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1; 

B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1

In vivo efficacy of anti-human PD-1 antibody

from clipboard


Antitumor activity of anti-human PD-1 antibodies in B-hPD-1 plus/PD-L1 mice. Anti-human PD-1 antibody pembrolizumab (in house) and nivolumab (in house) inhibited the growth of B-hPD-L1 MC38 plus in B-hPD-1 plus/PD-L1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into B-hPD-1 plus/PD-L1 mice (female, 8-week-old, n=6). Mice were grouped when tumor volume reached approximately 80-120 mm3, at which time they were treated with anti-human PD-1 antibodies with doses indicated in panel. (A) Tumor volume and body weight of mice treated with pembrolizumab. (B) Tumor volume and body weight of mice treated with nivolumab. Results showed that pembrolizumab and nivolumab were both efficacious in controlling tumor growth in B-hPD-1 plus/PD-L1 mice. The tumor inhibitory effects were dose-dependent. The results demonstrate that the B-hPD-1 plus/PD-L1 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-1 antibodies. Values are expressed as mean ± SEM.

Percentages of leukocytes in CD45+ TILs

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.

Percentages of leukocyte subpopulations in TILs

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.

Percentages of hPD-1+ cells in TILs

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.

Percentages of hPD-L1+ cells in tumor tissue

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.

Percentages of activated cells

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.

Expression levels of hPD-1 on TILs

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.

Expression level of hPD-L1 on TILs

from clipboard


Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.